Abstract: The present invention provides a tricyclic compound, its preparation method and medical use. The tricyclic compound is a compound having the structure of the following formula (I), and its pharmaceutically acceptable salt, prodrug, tautomer, stereoisomers or mixtures of stereoisomers. The compound of the present invention has significant activity of antagonizing histamine H1 receptor, and has lower anti-M-choline side effects and lower hERG toxicity, Wherein the group is defined as described in the specification.

Abstract: The present disclosure relates to the field of pharmaceutical chemistry, in particular to a class of PARP/PI3K double-target inhibitors (I) containing structures of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine and phthalazin-1(2H)-one and a preparation method thereof. As proved by pharmacodynamic tests, the compounds of the present disclosure have PARP/PI3K double-target inhibitory activity and can be used for anti-tumor.

Abstract: The disclosure relates to the field of pharmaceutical technology, in particular, to a compound pharmaceutical composition for treating skin inflammatory diseases, which is characterized in that an active ingredient of the compound pharmaceutical of the disclosure is composed of tofacitinib and crisaborole, and the composition has a stronger therapeutic effect and a lower dosage with a significant synergistic therapeutic effect. The pharmaceutical composition of the disclosure can be used to treat skin inflammatory diseases.

Abstract: The disclosure relates to the field of medicinal chemistry, in particular, to a class of small molecule compounds for inhibiting phosphodiesterase 4 (I), a preparation method thereof and a pharmaceutical composition comprising the compound. The pharmacodynamic test proves that the compound of the disclosure has the inhibitory activity of PDE-4 enzyme and the efficacy of inflammation treatment.

Abstract: Embodiments of this application disclose a charging management method, a user plane function entity, and a control plane function entity. The method includes: receiving, by a UP, a first usage reporting rule (URR) and a second URR sent by a CP, where the first URR is correlated with the second URR; when usage information on the UP reaches a threshold of the first URR, obtaining, by the UP, usage information corresponding to the first URR and usage information corresponding to a third URR correlated with the first URR; and sending, by the UP to the CP, the usage information corresponding to the first URR and the usage information corresponding to the third URR, so that the CP generates a charging data record based on the usage information corresponding to the first URR and the usage information corresponding to the third URR.

Abstract: The present disclosure relates to the field of pharmaceutical chemistry, in particular to a class of PARP/PI3K double-target inhibitors (I) containing structures of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine and phthalazin-1(2H)-one and a preparation method thereof. As proved by pharmacodynamic tests, the compounds of the present disclosure have PARP/PI3K double-target inhibitory activity and can be used for anti-tumor.

Abstract: The disclosure relates to the field of medicinal chemistry, in particular, to a class of small molecule compounds for inhibiting phosphodiesterase 4 (I), a preparation method thereof and a pharmaceutical composition comprising the compound. The pharmacodynamic test proves that the compound of the disclosure has the inhibitory activity of PDE-4 enzyme and the efficacy of inflammation treatment.

Abstract: The disclosure relates to the field of pharmaceutical technology, in particular, to a compound pharmaceutical composition for treating skin inflammatory diseases, which is characterized in that an active ingredient of the compound pharmaceutical of the disclosure is composed of tofacitinib and crisaborole, and the composition has a stronger therapeutic effect and a lower dosage with a significant synergistic therapeutic effect. The pharmaceutical composition of the disclosure can be used to treat skin inflammatory diseases.

Abstract: Embodiments of this application disclose a charging management method, a user plane function entity, and a control plane function entity. The method includes: receiving, by a UP, a first usage reporting rule (URR) and a second URR sent by a CP, where the first URR is correlated with the second URR; when usage information on the UP reaches a threshold of the first URR, obtaining, by the UP, usage information corresponding to the first URR and usage information corresponding to a third URR correlated with the first URR; and sending, by the UP to the CP, the usage information corresponding to the first URR and the usage information corresponding to the third URR, so that the CP generates a charging data record based on the usage information corresponding to the first URR and the usage information corresponding to the third URR.

Abstract: Embodiments of this application disclose a charging management method, a user plane function entity, and a control plane function entity. The method includes: receiving, by a UP, a first usage reporting rule (URR) and a second URR sent by a CP, where the first URR is correlated with the second URR; when usage information on the UP reaches a threshold of the first URR, obtaining, by the UP, usage information corresponding to the first URR and usage information corresponding to a third URR correlated with the first URR; and sending, by the UP to the CP, the usage information corresponding to the first URR and the usage information corresponding to the third URR, so that the CP generates a charging data record based on the usage information corresponding to the first URR and the usage information corresponding to the third URR.

Abstract: A charging method, a network device, and a system, where the method includes performing, by a policy and charging enforcement function (PCEF), online charging for user equipment (UE), switching, by the PCEF, the UE from online charging to offline charging, and starting an offline timer when an online charging system (OCS) is unavailable, and restoring, by the PCEF, the UE from offline charging to online charging when the PCEF learns, before the offline timer expires, that the OCS becomes available. Hence, after a user is switched to offline charging, an online charging function can be recovered in a timely manner when the OCS becomes available. In this way, a user account overdraft risk possibly existing in an offline charging process is mitigated, and deactivation of the user can be avoided in the solutions, thereby improving user experience.

Abstract: Embodiments of this application disclose a charging management method, a user plane function entity, and a control plane function entity. The method includes: receiving, by a UP, a first usage reporting rule (URR) and a second URR sent by a CP, where the first URR is correlated with the second URR; when usage information on the UP reaches a threshold of the first URR, obtaining, by the UP, usage information corresponding to the first URR and usage information corresponding to a third URR correlated with the first URR; and sending, by the UP to the CP, the usage information corresponding to the first URR and the usage information corresponding to the third URR, so that the CP generates a charging data record based on the usage information corresponding to the first URR and the usage information corresponding to the third URR.

Abstract: Embodiments of the present invention provide an event reporting method and an apparatus. The method includes: receiving, by a policy and charging rules function PCRF entity, a first message sent by a traffic detection function TDF entity, where the first message includes a start event, and the start event is used to notify the PCRF entity that a data stream starts to be transmitted; sending, by the PCRF entity, a second message to a PCEF entity or the TDF entity, where the second message is used by the PCEF entity or the TDF entity to send a stop event to the PCRF entity, and the stop event is used to notify the PCRF entity that the transmission of the data stream stops; and receiving, by the PCRF entity, the stop event sent by the PCEF entity or the TDF entity.

Abstract: A charging method, a network device, and a system, where the method includes performing, by a policy and charging enforcement function (PCEF), online charging for user equipment (UE), switching, by the PCEF, the UE from online charging to offline charging, and starting an offline timer when an online charging system (OCS) is unavailable, and restoring, by the PCEF, the UE from offline charging to online charging when the PCEF learns, before the offline timer expires, that the OCS becomes available. Hence, after a user is switched to offline charging, an online charging function can be recovered in a timely manner when the OCS becomes available. In this way, a user account overdraft risk possibly existing in an offline charging process is mitigated, and deactivation of the user can be avoided in the solutions, thereby improving user experience.

Abstract: The present invention refers to diene-based unsaturated polymer latex particles having a particle size measured as d90-value of less than 60 nm and a method for their production. Methods for using the diene-based polymer latex as rubber and for conversion to hydrogenated polymers, with reduced gel formation, are also disclosed.

Abstract: The invention provides a session restoration method, device and system. The method includes: receiving, by a standby PCRF, a CCR-U message sent by a PCEF, where the CCR-U message is sent by the PCEF after determining that a session needs to be updated; and according to the CCR-U message, re-establishing, by the standby PCRF, a session and making a PCC policy decision. According to embodiments of the present invention, signaling interaction overheads can be reduced, and a signaling processing capability of a standby PCRF can be improved.

Abstract: Ligustrazine aromatic acid ether derivative of general formula I, its preparation method, pharmaceutical composition and application, wherein Ar is selected from aryl substituted aryl and substituted styryl, R is selected from hydrogen and alkyl with no more than 6 carbon atoms.

Abstract: The present invention refers to diene-based unsaturated polymer latex particles having a particle size measured as d90-value of less than 60 nm and a method for their production. Methods for using the diene-based polymer latex as rubber and for conversion to hydrogenated polymers, with reduced gel formation, are also disclosed.

Abstract: The present invention refers to diene-based unsaturated polymer latex particles having a particle size measured as d90-value of less than 60 nm and a method for their production.

Abstract: Ligustrazine aromatic acid ether derivative of general formula I, its preparation method, pharmaceutical composition and application, wherein Ar is selected from aryl substituted aryl and substituted styryl, R is selected from hydrogen and alkyl with no more than 6 carbon atoms.